Effect of phytate on hypercalciuria secondary to bone resorption in patients with urinary stones

You have accessJournal of UrologyCME1 May 2022PD05-04 EFFECT OF PHYTATE ON HYPERCALCIURIA SECONDARY TO BONE RESORPTION IN PATIENTS WITH URINARY STONES Jordi Guimera, Ana Martinez Moreno, Jose Luis Bauza Quetglas, Pilar Sanchis Cortes, Enrique Pieras Ayala, and Feliciano Grases Freixedas Jordi GuimeraJordi Guimera More articles by this author , Ana Martinez MorenoAna Martinez Moreno More articles by this author , Jose Luis Bauza QuetglasJose Luis Bauza Quetglas More articles by this author , Pilar Sanchis CortesPilar Sanchis Cortes More articles by this author , Enrique Pieras AyalaEnrique Pieras Ayala More articles by this author , and Feliciano Grases FreixedasFeliciano Grases Freixedas More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002524.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Hypercalciuria is the most common urinary alteration in patients with kidney stones. Multiple studies reported associations of hypercalciuria with renal lithiasis and elevated bone resorption. Phytate (inositol hexakisphosphate, InsP6) can inhibit kidney stone formation and bone resorption. The main objective of this study is to evaluate the effect of phytate supplements on calciuria in patients with urinary stones and elevated bone resorption. The secondary objective is to analyze the therapeutic effect of phytate based on measurements of serum markers of bone resorption. METHODS: This controlled randomized study enrolled patients according to predefined inclusion and exclusion criteria, and randomized them into two groups. Patients in the phytate group received a 380 mg capsule of calcium-magnesium InsP6 (Broken Laboratories®) every 24 h for 3 months and patients in the control group received no treatment. All included patients were male or female, 18 to 65 years-old, had hypercalciuria (>250 mg/24 h), had a ß-Crosslaps level greater than 0.4 ng/mL, and had bone densitometry results indicative of osteopenia or osteoporosis in the femur and/or spine. The baseline characteristics of patients in both groups were compared using a t-test for independent samples (quantitative data) and a chi-square test or Fisher’s exact test (categorical data). The inter and intragroup comparisons were made using t-test for paired and independent samples and ANCOVA. RESULTS: At study onset, calciuria was 321±52 mg/24 h in the phytate group and 305±57 mg/24 h in the control group (p>0.05). At 3 months, calciuria was significantly lower in the phytate group than the control group (226±45 mg/24 h vs. 304±58 mg/24 h, p<0.05). At study onset, the mean ß-CrossLaps level was 1.25±0.72 ng/mL in the phytate group and 0.57±0.13 ng/mL in the control group (p<0.05). However, at 3 months, the ß-CrossLaps level was significantly lower in the phytate group than in the control group (0.57±0.13 ng/mL vs. 0.77±0.42 ng/mL, p<0.05). Thus, calciuria decreased by 29% (±12) in the phytate group and 0.1% (±14) in the control group B (p<0.05) and the ß-CrossLaps level decreased by 35% (±15) in the phytate group and 0.6% (±14) in the control group (p<0.05). CONCLUSIONS: Phytate reduced calciuria in patients with hypercalciuria secondary to bone resorption. The ß-CrossLaps assay was effective for evaluating the efficacy of phytate on hypercalciuria during follow-up. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e87 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jordi Guimera More articles by this author Ana Martinez Moreno More articles by this author Jose Luis Bauza Quetglas More articles by this author Pilar Sanchis Cortes More articles by this author Enrique Pieras Ayala More articles by this author Feliciano Grases Freixedas More articles by this author Expand All Advertisement PDF downloadLoading ...